Abstract
Pneumococcal disease remains a major cause of morbidity and mortality globally despite the widespread introduction of pneumococcal conjugate vaccines (PCVs). Vaccine-induced antibodies can protect against both invasive pneumococcal disease (IPD) and colonisation. An aggregate correlate of protection (CoP) of 0·35 μg/mL for IPD has been used for PCV licensure;1 however, there is increasing evidence that CoPs can differ between serotypes,2 the clinical target of protection (IPD or colonisation), and the income status (or exposure risk) of the country.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
